Invited Commentary

Observational Evidence Calls for Deimplementation of Routine Preoperative Urine Screening

Barbara W. Trautner, MD, PhD

In this issue of *JAMA Surgery*, a retrospective cohort study by Gallegos Salazar et al¹ provides high-quality evidence that preoperative screening urine cultures are not associated with improvements in infectious outcomes. Specifically, the authors



Related article

examined all major cardiac, orthopedic joint replacement, and vascular surgery

procedures within the US Department of Veterans Affairs health care system from 2008 to 2013, identifying 17 611 patients with a preoperative urine culture who had either a negative culture result or asymptomatic bacteriuria (ASB), defined as a positive culture result without urinary symptoms. No significant differences in risk of surgical site infection (SSI) (including prosthetic valve or joint infections) or urinary tract infection (UTI) were identified between patients with negative culture results and those with ASB in the overall cohort. Effective antibiotic treatment of the organisms causing ASB did not lower the risk of SSI or UTI.

The study's strong methods and biological plausibility support the validity of the findings. All the cases in this large national cohort had been reviewed prospectively through the Veterans Affairs Surgical Quality Improvement Program using robust review criteria and case definitions. Asymptomatic bacteriuria is a well-established marker for poor health status and comorbidities, 2 so the elevated risk of SSI in the cardiac surgery subgroup likely arose through common risk factors for ASB and SSI, such as diabetes. The finding that the urine and wound organisms matched in only 2 cases in the entire cohort (both *Staphy*-

lococcus aureus) demonstrates that ASB is not in the causal pathway for SSI. Given the low frequency of positive urine culture results identified by screening and the infrequency of SSI and postoperative UTI, a randomized clinical trial will not be possible. This study is likely to become the definitive investigation of this topic despite the shortcoming of the predominantly male cohort.

A clear picture emerges: while ASB is a risk marker for poor outcomes, screening for and treating ASB will not improve post-operative infectious outcomes. These findings will be greeted with joy by infectious diseases physicians far and wide. We are facing a global crisis of antimicrobial resistance in which our future world may lack effective antimicrobial agents. A positive urine culture result is a powerful stimulus for antibiotic prescribing. Interventions that have focused on reducing urine cultures or suppressing their results have reduced the antibiotic treatment of ASB. Liminating routine preoperative urine cultures will reduce the number of positive urine culture results in asymptomatic patients, in turn reducing unnecessary antibiotic use.

Surgeons should likewise rejoice that we have strong evidence to support eliminating routine preoperative urine cultures. Effective antibiotics make complex surgeries possible and good infectious outcomes probable. In terms of the urgent need to preserve antibiotics for the future, the interests of surgeons and infectious diseases physicians are aligned. Deimplementing an entrenched custom is challenging, but surgeons and infectious diseases physicians together can bring this change for the benefit of patients now and in the future.

ARTICLE INFORMATION

Author Affiliation: Section of Health Services Research, Michael E. DeBakey Veterans Affairs Medical Center, Baylor College of Medicine, Houston, Texas.

Corresponding Author: Barbara W. Trautner, MD, PhD, Michael E. DeBakey Veterans Affairs Medical Center, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030 (trautner@bcm.edu).

Published Online: December 12, 2018. doi:10.1001/jamasurg.2018.4765

Conflict of Interest Disclosures: Dr Trautner reports receiving grant support from the Veterans Affairs Health Services Research and Development Service and Zambon and personal fees from Zambon and Paratek. She has written book chapters and manuscripts with the senior author of the article discussed in this Invited Commentary.

REFERENCES

- 1. Gallegos Salazar J, O'Brien W, Strymish J, Itani K, Branch-Elliman W, Gupta K. Association of screening and treatment for preoperative asymptomatic bacteriuria with postoperative outcomes among US veterans [published online December 12, 2018]. *JAMA Surg.* doi:10.1001 /jamasurg.2018.4759
- 2. Nicolle LE, Bradley S, Colgan R, Rice JC, Schaeffer A, Hooton TM; Infectious Diseases Society of America; American Society of Nephrology; American Geriatric Society. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. *Clin Infect Dis*. 2005;40(5): 643-654. doi:10.1086/427507
- **3**. World Health Organization. Global action plan on antimicrobial resistance. http://www.who.int

/antimicrobial-resistance/global-action-plan/en/. Accessed October 12, 2018.

- 4. Leis JA, Rebick GW, Daneman N, et al. Reducing antimicrobial therapy for asymptomatic bacteriuria among noncatheterized inpatients: a proof-of-concept study. *Clin Infect Dis*. 2014;58 (7):980-983. doi:10.1093/cid/ciu010
- Trautner BW, Grigoryan L, Petersen NJ, et al. Effectiveness of an antimicrobial stewardship approach for urinary catheter-associated asymptomatic bacteriuria. *JAMA Intern Med*. 2015; 175(7):1120-1127. doi:10.1001/jamainternmed.2015 1878
- **6**. van Bodegom-Vos L, Davidoff F, Marang-van de Mheen PJ. Implementation and de-implementation: two sides of the same coin? *BMJ Qual Saf*. 2017;26(6):495-501. doi:10.1136 /bmjqs-2016-005473

JAMA Surgery | Original Investigation

Association of Screening and Treatment for Preoperative Asymptomatic Bacteriuria With Postoperative Outcomes Among US Veterans

Jaime Gallegos Salazar, MD; William O'Brien, MS; Judith M. Strymish, MD; Kamal Itani, MD; Westyn Branch-Elliman, MD, MSc; Kalpana Gupta, MD, MPH

IMPORTANCE Limited data suggest that screening for asymptomatic bacteriuria (ASB) prior to nonurologic procedures is not useful. However, high-quality evidence to support consensus recommendations and influence clinical practice is lacking.

OBJECTIVE To characterize the association between detection and treatment of preoperative ASB and postoperative outcomes.

DESIGN, SETTING, AND PARTICIPANTS This retrospective cohort study involved patients, predominantly male veterans, who underwent surgical procedures in 109 US facilities within the US Department of Veterans Affairs health care system from October 1, 2008, to September 30, 2013. Participants included patients (n = 68 265) who had cardiac, orthopedic, or vascular surgical procedures. Each received a planned clinician review of complete medical records for antimicrobial prophylaxis as well as 30-day surgical-site infection (SSI) and urinary tract infection (UTI) outcomes, and each had a preoperative urine culture result available within the 30 days prior to the procedure. Data analysis was performed from December 2016 to August 2018.

MAIN OUTCOME AND MEASURES The primary outcome was the association between preoperative ASB and postoperative SSI. The secondary outcomes included postoperative UTI and the association between antimicrobial therapy for ASB and postoperative infectious outcomes.

RESULTS In total, 68 265 patients (65 664 [96.2%] were men and 2601 [3.8%] were women, with a mean [SD] age of 64.6 [9.2] years) were identified, and 17 611 (25.8%) were eligible for inclusion in the primary analysis. Preoperative urine cultures were performed in 17 749 (26.0%) patients, and the results were positive in 755 (4.3%), of which 617 (81.7%) were classified as ASB. With adjustments for age, American Society of Anesthesiologists class, smoking status, race/ethnicity, sex, and diabetes status, patients with or without ASB had similar odds of SSI (2.4% vs 1.6%; adjusted odds ratio [aOR], 1.58; 95% CI, 0.93-2.70; P = .08). Receipt of antimicrobial therapy with activity against the ASB organism was not associated with a reduced SSI risk (aOR, 1.01; 95% CI, 0.28-3.65; P = .99). Urinary tract infection occurred in 14 (3.3%) of 423 patients with ASB and 196 (1.5%) of 12 913 patients without ASB (aOR, 1.42; 95% CI, 0.80-2.49; P = .22). Treatment or prophylaxis for the ASB organism similarly was not associated with reduced odds of postoperative UTI (aOR 0.68; 95% CI, 0.20-2.30; P = .54). The ASB organisms matched a postoperative wound culture in 2 cases, both *Staphylococcus aureus*.

CONCLUSIONS AND RELEVANCE The findings of this study suggest that receipt of antimicrobial therapy with activity against ASB organisms identified in preoperative urine cultures was not associated with reductions in the risk for postoperative infections, including UTI and SSI; such findings suggest there is evidence for discontinuing the practice of screening and treatment for preoperative ASB.

JAMA Surg. doi:10.1001/jamasurg.2018.4759 Published online December 12, 2018. Invited Commentary

Author Affiliations: Department of Medicine, VA Boston Healthcare System, Boston, Massachusetts (Salazar, Strymish, Branch-Elliman, Gupta); Department of Medicine, Boston University School of Medicine, Boston, Massachusetts (Salazar, Itani, Gupta); VA Center for Healthcare Organization and Implementation Research, Boston, Massachusetts (O'Brien, Branch-Elliman, Gupta): Department of Medicine, Harvard Medical School, Boston, Massachusetts (Strymish, Itani, Branch-Elliman): Department of Surgery, VA Boston Healthcare System, Boston, Massachusetts (Itani); Department of Surgery, Boston University School of Medicine, Boston, Massachusetts

Corresponding Author: Kalpana Gupta, MD, MPH, Department of Medicine, VA Boston Healthcare System, 1400 VFW Pkwy, West Roxbury, MA 02132 (kalpana.gupta @va.gov).

symptomatic bacteriuria (ASB) is associated with postoperative adverse events, including increases in surgical-site infection (SSI) and urinary tract infection (UTI), after nonurologic procedures.^{1,2} However, whether preoperative screening of urine cultures with antimicrobial therapy directed toward colonizing bacterial organisms improves clinical outcomes remains controversial.3 The 2018 update to the ASB guidelines by the Infectious Diseases Society of America recommends against this practice but without supporting high-quality evidence.⁴ Concern for bacterial translocation from the bladder with resultant contamination of the surgical site is high, particularly during procedures in which foreign material is implanted, such as orthopedic total joint replacement and cardiac valve replacement. In part because of the lack of concrete evidence supporting or refuting screening with directed treatment, clinical practice patterns vary widely, with some centers obtaining preoperative urine cultures as part of the standard of care.5-7

The associations between UTI and prosthetic joint infection after total joint replacement procedures were first described in the 1970s. 1,8-12 More recently, a large observational study reported a 3-fold rise in prosthetic joint infections among patients with ASB. 1 Of importance, Sousa et all also found that the SSIs were usually not caused by the organism identified in the preoperative urine cultures; the discordance between the uropathogen and the SSI pathogen suggests that ASB is a risk marker for SSI but is not part of the causal pathway. 1 This premise is further supported by several small studies that found antimicrobial therapy directed toward the uropathogen in the preoperative period does not improve postoperative outcomes. 1,13-15

Mayne et al¹⁶ highlighted the challenges of definitively answering whether screening for and treatment of ASB can positively affect postoperative clinical outcomes. They estimated that "a trial comparing screening and treatment of ASB with no treatment would require at least 50,000 patients in each arm to detect a difference in infection risk of 0.15% and is, therefore, in practice, impossible. Bigger and better observational research is still possible, however, and should be a priority."16(p1) Thus, we sought to use a large, multicenter, national cohort to measure the association between ASB and key postoperative infectious outcomes, including SSI and UTI, and to determine if antimicrobial therapy directed against the colonizing organism was associated with reduced rates of infection after major cardiac, orthopedic, and vascular surgical procedures. A secondary aim was to evaluate if the colonizing organism matched the infecting organism in cases of SSI and UTI.

Methods

Prior to data collection and analysis, all study procedures, including waiver of informed consent, were approved by the VA Boston Healthcare System Institutional Review Board. Data analysis was performed from December 2016 to August 2018.

Key Points

Question Is routine screening and treatment for asymptomatic bacteriuria in patients undergoing orthopedic, cardiac, or vascular surgical procedures warranted?

Findings In this national cohort study of 68 265 US veterans, preoperative asymptomatic bacteriuria was associated with higher rates of postoperative urine cultures with bacteriuria among patients who underwent cardiac, orthopedic, and vascular surgical procedures and with 30-day surgical-site infection in patients who had a cardiac surgical procedure. However, active antimicrobial therapy with activity against the uropathogen was not associated with improvement in any measurable postoperative clinical outcome.

Meaning Findings from this study provide evidence against screening or treating preoperative asymptomatic bacteriuria.

Cohort Development

This study included all patients who underwent major cardiac (bypass or valve replacement), orthopedic knee and hip total joint replacement (eg, implant procedures), or vascular surgical procedures in 109 US facilities within the US Department of Veterans Affairs (VA) health care system from October 1, 2008, to September 30, 2013. A trained clinician performed a prospectively planned clinical record review for antimicrobial prophylaxis regimen (under the Reporting, Analytics, Performance, Improvement, and Deployment [RAPID] program) and for 30-day National Healthcare Safety Networkdefined SSI and UTI postoperative outcomes (under the VA Surgical Quality Improvement Program [VASQIP]), and these patients underwent a urine culture during the 30-day preoperative period. The VASQIP assesses approximately 70% of surgical procedures within the VA system on the basis of a validated methodology for case review selection.¹⁷

Deep and organ/space SSI outcome was available for all surgical procedures during the study period. Per the planned VASQIP methodology, superficial SSI was assessed from 2012 to 2013 for cardiac surgical procedures and in all study years for the noncardiac procedures. Postoperative UTI was not assessed for patients who had cardiac surgical procedures.

Definitions

The decision for preoperative urine culture screening was directed by facility and/or surgeon practice. Urine culture results were defined as positive if they had 10⁵ or more colony-forming units of any bacterial organism isolated. All other urine culture results were classified as negative. The clinical records of all patients with a positive urine culture result were manually reviewed by an infectious diseases physician on our team (J.G.S.) using a standardized data collection form to assess for lower UTI symptoms (ie, dysuria, frequency, urgency, and new hematuria) and for systemic symptoms (eg, fever or systemic inflammatory response syndrome [SIRS] and confusion or mental status changes). Patients with any symptom were classified as symptomatic UTI, and patients without any documented clinical symptoms were classified as having ASB. ⁴ The classification of ASB or UTI was adjudicated by

a second infectious diseases physician on our team (J.M.S.), and the robustness of this classification was assessed through a sensitivity analysis.

Antimicrobial regimens ordered anytime between the ASB culture date and the surgical procedure date were classified as active or inactive for the ASB organism on the basis of organism type and antimicrobial resistance profile. For cultures with more than 1 organism, antimicrobial therapy was considered inactive unless all organisms were susceptible to the regimen.

Outcomes

The 30-day SSI and UTI outcomes were measured by VASQIP according to the SSI and UTI surveillance definitions from the National Healthcare Safety Network. To expand the window to capture 90-day outcomes for cardiac and orthopedic implants, the wound culture results collected up to 90 days after the surgical procedure date were extracted electronically, as were the 90-day postoperative *Clostridium difficile* results and 30-day urine culture results. A wound culture result was classified as positive if any organism was grown in a culture obtained from a topography that was potentially associated with the surgical site. Cultures obtained for surveillance, cultures from foreign bodies such as central lines, and cultures from distant body sites were excluded.

Power and Sample Size


The sample size of the cohort was determined by the number of surgical procedures manually reviewed and provided by VASQIP. The expected incidence of patients with SSI without ASB was estimated at 2%, based on estimates used in the previous literature. ^{1,18} Using this estimate, this study had greater than 80% power to identify a 2-fold higher rate of SSI among patients with ASB compared with those without ASB. Using an estimated SSI risk of 2% in patients treated for ASB, we had 72% power (1-tail test) to find a 3-fold increased risk of SSI among 132 patients who were not treated for ASB compared with 485 patients who received active treatment.

Statistical Analysis

Logistic regression analysis models adjusted for age, American Society of Anesthesiologists (ASA) physical status class, smoking status, race/ethnicity, sex, and diabetes status and then stratified by type of surgical procedure were used to measure the association between preoperative ASB and postoperative SSI, UTI, positive urine culture, and positive wound culture results. Race/ethnicity was classified as reported in the electronic medical records and included for purposes of describing the population. Among patients with ASB, we assessed the association between receipt of active antimicrobial therapy and/or active surgical prophylaxis and postoperative infectious outcomes. We used 2-tailed t test for continuous variables and χ^2 for categorical variables, with P = .05 as the threshold for significance. All analyses were done in SAS, version 9.4 (SAS Institute).

A sensitivity analysis was performed to determine if expanding the control group (no ASB) to include patients without urine culture results changed the findings. Definition of

Figure 1. Diagram of Eligible and Included Patients



the exposure group (ASB) remained the same. A second sensitivity analysis was performed to determine if expanding the exposure group to include all patients with a positive urine culture result regardless of the presence of symptoms changed the results. All other definitions remained the same.

Results

In total, 68 265 patients (65 664 [96.2%] were men and 2601 [3.8%] were women, with a mean [SD] age of 64.6 [9.2] years) who underwent cardiac, orthopedic, and vascular surgical procedures with manually validated SSI outcomes and antimicrobial prophylaxis regimens were identified. Of these patients, 17 749 (26.0%) had a urine culture and 17 611 (25.8%) were eligible for inclusion in the primary analysis (**Figure 1**).

Among the 17749 urine cultures performed, 755 (4.3%) had a positive result, of which 617 (81.7%) were designated as preoperative ASB. The proportion of preoperative urine cultures varied by surgical type, including 4324 (20%) obtained prior to cardiac surgical procedures, 12 399 (32%) prior to orthopedic surgical procedures, and 1027 (12.5%) prior to vascular surgical procedures. Urine cultures were performed within a median (interquartile range [IQR]) of 10 (4-18) days prior to the surgical procedure date. The mean age, sex, race/ethnicity, diabetes status, and smoking status were similar among the 50 516 patients without a preoperative urine culture compared with the 17 749 with a preoperative urine culture. Patients with ASB were older (mean [SD] age, 69.6 [10.4] years), less likely to be male (539 [87.4%]), and more likely to have diabetes (183 [29.7%]) compared with patients without ASB (Table 1).

Association Between ASB and SSI

In total, 283 SSI (1.6%) were identified in the 30-day postoperative period among the 17 611 patients who had preoperative urine cultures in the absence of UTI symptoms. Among the 617 patients with ASB, 15 (2.4%) had an SSI compared with 268 (1.6%) of the 16 994 patients without ASB. After adjusting for age, ASA class, smoking status, race/ethnicity, sex, and diabetes status, no statistically significant difference in rates

Table 1. Demographics of Surgical Patients Stratified by Preoperative Urine Culture Results

	No. (%)						
	Preoperative Cult						
			Positive Result				
Characteristic	Not Performed	Negative Result	ASB	Symptomatic	Total		
All patients	50 516	16 994	617	138	68 265		
Male sex	48 825 (96.7)	16 173 (95.2)	539 (87.4)	127 (92.0%)	65 664 (96.2)		
Age, mean (SD), y	64.5 (9.1)	64.8 (9.4)	69.6 (10.4)	71.5 (10.0)	64.6 (9.2)		
Diabetes	14 237 (28.2)	4227 (24.9)	183 (29.7)	44 (31.9)	18 691 (27.4)		
Current smoker	15 206 (30.1)	4325 (25.5)	150 (24.3)	34 (24.6)	19715 (28.9)		
Surgical cohort							
Cardiac	17 076 (33.8)	4081 (24.0)	194 (31.4)	48 (34.8)	21 399 (31.3)		
Orthopedic	26 281 (52.0)	11 949 (70.3)	376 (60.9)	74 (53.6)	38 680 (56.7)		
Vascular	7159 (14.2)	964 (5.7)	47 (7.6)	16 (11.6)	8186 (12.0)		
Race/ethnicity ^a							
White	39 651 (78.5)	13 565 (79.8)	486 (78.8)	104 (75.4)	53 809 (78.8)		
Black	6783 (13.4)	2117 (12.5)	79 (12.8)	22 (15.9)	9001 (13.2)		
Other	4082 (8.1)	1312 (7.7)	52 (8.4)	12 (8.7)	5438 (8.0)		
Ethnicity ^a							
Hispanic	2307 (4.6)	878 (5.2)	33 (5.3)	6 (4.3)	3224 (4.7)		

Abbreviation: ASB, asymptomatic bacteriuria.

Table 2. Frequency and Adjusted Risk of 30-Day Postoperative Outcomes in Patients With ASB or Without ASB, Stratified by Surgical Type^a

	No./Total No. (%)			
Cohort	Preoperative ASB Not Identified (n = 16 994)	Preoperative ASB Identified (n = 617)	aOR (95% CI)	P Value
Whole cohort				
SSI	268/16 994 (1.6)	15/617 (2.4)	1.58 (0.93-2.70)	.08
UTI	196/12913 (1.5)	14/423 (3.3)	1.42 (0.80-2.49)	.22
Positive wound culture result ^b	497/16 994 (2.9)	23/617 (3.7)	1.20 (0.78-1.85)	.39
Positive urine culture result	616/16 994 (3.6)	83/617 (13.5)	2.87 (2.28-3.70)	<.001
Cardiac procedure				
SSI	41/4081 (1.0)	6/194 (3.1)	3.06 (1.27-7.30)	.01
UTI	NA	NA	NA	NA
Positive wound culture result ^b	149/4081 (3.7)	9/194 (4.6)	1.22 (0.61-2.45)	.57
Positive urine culture result	195/4081 (4.8)	31/194 (16)	3.11 (2.04-4.74)	<.001
Orthopedic procedure				
SSI	154/11949 (1.3)	5/376 (1.3)	1.19 (0.48-2.96)	.69
UTI	164/11949 (1.4)	14/376 (3.7)	1.71 (0.97-3.04)	.06
Positive wound culture result ^b	226/11949 (1.9)	6/376 (1.6)	0.86 (0.37-1.96)	.72
Positive urine culture result	364/11949 (3.0)	46/376 (12.2)	2.79 (1.98-3.93)	<.001
Vascular procedure				
SSI	73/964 (7.6)	4/47 (8.5)	1.10 (0.37-3.23)	.85
UTI	32/964 (3.3)	0/47 (0)	NA	.98
Positive wound culture result ^b	122/964 (12.7)	8/47 (17.0)	1.36 (0.61-3.04)	.44
Positive urine culture result	57/964 (5.9)	6/47 (12.8)	2.10 (0.84-5.25)	.11

Abbreviations: aOR, adjusted odds ratio; ASB, asymptomatic bacteriuria; NA, not applicable; SSI, surgical-site infection; UTI, urinary tract infection.

of SSI was identified in patients with or without ASB (adjusted odds ratio [aOR], 1.58; 95% CI, 0.93-2.70; P = .08) (Table 2). Adjusting for facility at the Veterans Integrated Ser-

vice Networks level did not change the risk for SSI (aOR, 1.67; 95% CI, 0.95-2.90). The lack of association persisted when the analysis was stratified by surgical type, except for cardiac sur-

^a Six percent of patients had missing race data, and 3% had missing ethnicity data.

^a Covariates included diabetes status, smoking status, American Society of Anesthesiologists score higher than 2, sex, and age.

^b Wound cultures were abstracted up to 90 days after surgical procedure.

gical procedures in which a 3-fold increase in the SSI rate was observed among preoperative patients with ASB compared with preoperative patients without ASB (6 of 194 [3.1%] vs 41 of 4081 [1.0%]; aOR, 3.06; 95% CI, 1.27-7.30) (Table 2).

Association Between ASB and UTI

The VASQIP assessment captured 210 UTIs after 13 336 orthopedic and vascular procedures (1.6%). Fourteen (3.3%) of 423 patients with ASB had a UTI, compared with 196 (1.5%) of 12 913 patients without ASB (aOR, 1.42; 95% CI, 0.80-2.49; P = .22 (Table 2).

Sensitivity Analyses

In sensitivity analyses, in which the control group was expanded from 16 994 with a known negative urine culture result to also include the 50 516 patients without a urine culture result, minimal differences were observed in the risk of SSI or UTI compared with the more restrictive control group. The risk of SSI among the 67510 patients without ASB identification was 2.1%, compared with 2.4% in patients with ASB (aOR, 1.17; 95% CI, 0.70-1.96; P = .55). Risk of UTI was 1.5% in 697 patients of the 46 353 expanded control group without ASB, compared with 3.3% in the ASB group (aOR, 1.46; 95% CI, 0.85-2.52; *P* = .17). Stratification across surgical types also demonstrated minimal changes in the OR when using the expanded control group definition. In a second sensitivity analysis that included all patients with positive urine culture results in the exposure group (including the 132 patients deemed to have symptoms consistent with possible UTI), the outcome of SSI also was not changed, compared with the more restrictive exposure group.

Association Between ASB and Other Postoperative Outcomes

Positive wound culture results from a potentially relevant body site were identified during the 90-day period after 520 surgical procedures. No statistically significant differences in the odds of positive wound culture results among patients with or without ASB were identified among the whole cohort or in the analysis stratified by surgical type.

During the 30-day postoperative period, 699 positive urine culture results (3.9%) were identified. The rate of positive postoperative urine culture results was higher among patients with ASB compared with patients without preoperative ASB (83 of 617 [13.5%] vs 616 of 16 994 [3.6%]; aOR, 2.87; 95% CI, 2.28-3.70; P < .001). The analysis stratified by surgical type had similar findings (Table 2).

We identified 128 cases of C difficile in the 90-day postoperative period. Five (0.8%) of 617 patients with ASB had C difficile compared with 123 (0.7%) of 16 994 patients without ASB (aOR, 0.82; 95% CI, 0.34-2.03; P = .67). Because all of the patients in the cohort received preoperative antimicrobial therapy (surgical prophylaxis at a minimum), stratification of C difficile rates according to antimicrobial exposure was not possible. Incidence of postoperative C difficile infection was similar across all surgical specialties.

Preoperative and Postoperative Microbiologic Results

The 617 preoperative ASB urine cultures included 249 (40.4%) *Escherichia coli* infection, 89 (14.4%) *Klebsiella pneumoniae*, 26 (4.2%) *Pseudomonas aeruginosa*, and 99 (16.0%) other gram-negative findings. Enterococci were the most common gram-positive organisms (94 of 617 [15.2%]), and 18 (2.9%) were *Staphylococcus aureus*. Among the ASB patients, 23 (3.7%) had a positive postoperative wound culture result. In 2 cases (0.3%), the ASB organism matched the organism in the postoperative wound culture result. In both cases, the organism was *S aureus*.

Among the 83 patients with a positive postoperative urine culture result, 41 (49.4%) had the same organism identified in the preoperative and postoperative urine culture results. Thirty-seven (90.2%) of the 41 organisms were gramnegative bacteria, and 24 (58.5%) were $E \, coli$.

Association of ASB Treatment With Postoperative Outcomes

Among the 617 patients with ASB, 342 (55.4%) received antimicrobial therapy prior to the surgical procedure; the antimicrobial therapy was active against the ASB pathogen in 288 cases (46.7%). In patients who did not receive active therapy prior to the surgical procedure, 197 (31.9%) received a surgical prophylaxis regimen with activity against the uropathogen, resulting in a total of 485 patients (78.6%) who received antimicrobial therapy with activity against the ASB pathogen either before the surgical procedure or as a surgical prophylaxis. The remaining 132 patients with ASB (21.4%) received no active antimicrobial therapy for their ASB organism, either as a preoperative therapy or as a surgical prophylaxis (Figure 2).

The incidence of SSI was slightly higher in patients who received either active therapy or prophylaxis (2.5%), compared with those who did not receive active therapy or prophylaxis (2.3%), but was not statistically different (aOR, 1.01; 95% CI, 0.28-3.65; P=.99) (Figure 2). Treatment or prophylaxis for the ASB organism similarly did not reduce the odds of postoperative UTI (aOR 0.68; 95% CI, 0.20-2.30; P=.54) (Figure 2A). The incidence of postoperative urine and wound cultures with positive results also did not differ statistically significantly by receipt of active antimicrobial therapy (Figure 2).


In the cardiac surgical procedure subgroup, SSI occurred more frequently (5 of 152 [3.3%]) in patients treated with active antimicrobial therapy or surgical prophylaxis compared with patients who did not receive any active therapy or prophylaxis (1 of 42 [2.4%]). However, this difference was not statistically significant (aOR, 1.71; 95% CI, 0.17-16.34).

Discussion


In this large cohort of veterans, preoperative ASB was associated with higher rates of positive postoperative urine culture results among patients who underwent cardiac, orthopedic, and vascular surgical procedures and was associated with 30-day SSI in patients who had cardiac surgical procedures. Of importance, active antimicrobial therapy directed toward the asymptomatic uropathogen was not associated with improve-

Figure 2. Forest Plots of the Adjusted Risk for Each Selected Outcome in Patients With Preoperative Asymptomatic Bacteriuria (ASB)


A Active antimicrobial therapy before surgery or as surgical prophylaxis







C Active antimicrobial surgical prophylaxis only



Patients who received active antimicrobial therapy (ie, agent with in vitro activity against all pathogens in the ASB urine culture, and not necessarily an intent to treat the ASB pathogen) before surgery or as a surgical prophylaxis (n = 485; A), active antimicrobial therapy before surgery but not as a prophylaxis (n = 92; B), and active antimicrobial therapy as a surgical prophylaxis but not before surgery (n = 197; C). Each group was compared with those who did not receive active antimicrobial therapy against the ASB organisms before surgery or as a surgical prophylaxis (n = 132). OR indicates odds ratio; SSI, surgical site infection; UTI, urinary tract infection.

ment in any measurable postoperative clinical outcome; the rates of manually determined SSI, UTI, and positive wound and urine culture results were the same in patients who were treated and in those who were untreated. These data, therefore, suggest that there is no clinical utility to preoperative screening of urine cultures for cardiac, orthopedic, and vascular surgical procedures. Furthermore, if urine cultures are obtained, there is no value in, and therefore no role for, providing treatment or expanded prophylaxis to sterilize the urine in the perioperative period. These data are strengthened by our ability to match organism, antimicrobial resistance profile, and antimicrobial receipt to demonstrate that active treatment was not associated with improvement in clinical outcomes.

Much of the published medical literature focuses on positive interventions. However, identifying interventions that do not improve clinical care but only escalate health care costs is equally important. The Choosing Wisely campaign highlights the importance of not treating ASB in most circumstances, given the concerns about the harms of antimicrobial use, such as adverse drug events, emergence of antimicrobial resistance, and increases in *C difficile* infection, without any demonstrated value. ¹⁹ However, in the setting of new hardware, surgeons often feel compelled to provide targeted therapy for any colonizing organism given a desire to prevent highly morbid postoperative infections, such as prosthetic joint infections. ^{3,18,20} These findings are underscored by multiple

investigations demonstrating that when urine culture results are positive, clinicians prescribe targeted therapy to treat the colonizing uropathogen²¹; the higher the colony count, the stronger the inclination to treat.²² An orthopedic study found that discontinuing routine urine culture screening led to reductions in antimicrobial prescriptions without increases in postoperative prosthetic joint infections.²³

This study provides strong evidence that the practice of screening for asymptomatic bacteriuria with directed antimicrobial therapy should be de-implemented given the lack of advantages, potential for antimicrobial-associated harm, and unnecessary medical costs. Furthermore, the risk of SSI did not change when we expanded the exposure group to include patients with symptoms potentially consistent with UTI or when we expanded the control group to include patients who did not have urine cultures (which counted them as not having ASB). Thus, the findings are robust and are reliable in settings with practice variations in urine culture screening and documentation of symptoms.

The ability to directly compare the preoperative uropathogen with the organism grown in postoperative wound cultures strengthens the argument against screening and prophylaxis. An important finding is that in no cases did the ASB organism match the organism found in a prosthetic joint infection. Only twice did the preoperative ASB organism match the postoperative pathogen; in both cases, the infecting organism was *S aureus* and the surgical type was cardiac.

The role that urinary colonization with Saureus plays in the future development of postoperative infections is unknown, and our data are not able to definitively answer how these cases should be managed clinically. In this large cohort that included more than 17 000 urine cultures, we identified only 2 matches. As skin organisms, staphylococcal species are the most common cause of SSI. Thus, the match in these 2 cases may have occurred simply by chance. However, the positive urine culture result may also be a possible risk marker for a high burden of staphylococcal colonization and high risk for future S aureus infection, but the urinary colonization may not itself be in the causal pathway. Because we only identified 2 matches, we did not have statistical power to measure the implications of antimicrobial prophylaxis for patients specifically colonized with Saureus. However, in cases in which methicillin-resistant strains are cultured, it may be prudent to manage patients with S aureus in their urine as colonized and to administer appropriate surgical prophylaxis and decolonization.

Limitations

This study has several limitations. First, it is limited by its observational and retrospective nature as well as the rarity of the events evaluated. In this cohort comprising more than 17 000 clean surgical procedures with an integrated electronic medical record that optimized the capture of exposure and outcome data, only 617 cases of ASB occurred. Thus, given the infrequency of ASB, study designs that can establish causality, such as randomized clinical trials, are not feasible. Previous studies that attempted to answer how ASB treatment affected postoperative outcomes hinted that treatment of ASB before orthopedic total joint replacement procedures was not associated with improvement in postoperative outcomes; however, these studies included only a single center and had limited statistical power because of their small sample size. ⁷ The

one randomized clinical trial that compared ASB treatment with no treatment included 46 cases of ASB in the active and control arms combined; thus, that trial did not have statistical power to measure the association between treatment and postoperative outcomes. 13 Although, to our knowledge, this study substantially expands on current evidence, it only had the power to detect a 3-fold difference in outcomes between the treatment and no treatment groups; thus, some patients possibly gained some advantages that were not detected in this analysis. However, the harms of antimicrobial treatment, such as increases in C difficile infections, acute kidney injury, allergic reactions, and other adverse events, likely exceed any value, which would not have been detected in a cohort this large. Second, the study population was primarily male, and we were not able to control for variables such as immunocompromise, which could affect generalizability. Third, the ability to adjust by surgeon-level data was also limited.

Conclusions

The routine screening of preoperative urine cultures prior to major cardiac, orthopedic, and vascular surgical procedures rarely identified ASB in the predominantly male population of this study. When present, ASB was associated with high rates of positive urine culture results during the postoperative period. However, active antimicrobial therapy was not associated with a reduced incidence of postoperative SSIs or UTIs, indicating that ASB is a marker for host risk of colonization but not in the causal pathway of infections. To our knowledge, this study is the largest and most robust investigation into urine culture screening to date. It provides strong evidence that preoperative screening may not be valuable and should be discontinued as routine clinical practice.

ARTICLE INFORMATION

Accepted for Publication: September 14, 2018.

Published Online: December 12, 2018. doi:10.1001/jamasurg.2018.4759

Author Contributions: Dr Gupta had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Gallegos Salazar, Strymish, Itani, Branch-Elliman, Gupta.

Acquisition, analysis, or interpretation of data: Gallegos Salazar, O'Brien, Strymish, Branch-Elliman, Gupta.

Drafting of the manuscript: Gallegos Salazar, O'Brien, Strymish, Branch-Elliman, Gupta. Critical revision of the manuscript for important intellectual content: Gallegos Salazar, O'Brien, Itani, Branch-Elliman, Gupta.

Statistical analysis: O'Brien, Branch-Elliman, Gupta. Administrative, technical, or material support: Gupta.

Supervision: Gupta.

Conflict of Interest Disclosures: Dr Itani reported receiving grants from Sanofi and Pfizer outside of the present study. Dr Gupta reported being an author in an upcoming update to the International

Infectious Diseases Guideline on Asymptomatic Bacteriuria. No other disclosures were reported.

Funding/Support: This study was funded by grant IIR 12-103 from the VA Health Services Research and Development (Dr Gupta) and by a Career Development Award from Veterans Integrated Service Network 1 (Dr Branch-Elliman).

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Meeting Presentations: This study was presented in a poster abstract session at IDWeek 2017; October 7, 2017; San Diego, California; and in a symposium at IDWeek 2018; October 7, 2018; San Diego, California.

Additional Contributions: We thank the following for their collaboration and resources: US Department of Veterans Affairs (VA) Office of Reporting, Analytics, Performance, Improvement, and Deployment (RAPID), VA Surgical Quality Improvement Program and the Surgical Quality Data Use Group (SQDUG), and VA Informatics and Computing Infrastructure. Review and approval of a

draft of this article was performed by RAPID and SQDUG staff, per the respective data use agreements.

REFERENCES

- 1. Sousa R, Muñoz-Mahamud E, Quayle J, et al. Is asymptomatic bacteriuria a risk factor for prosthetic joint infection? *Clin Infect Dis*. 2014;59(1):41-47. doi:10.1093/cid/ciu235
- 2. Ollivere BJ, Ellahee N, Logan K, Miller-Jones JC, Allen PW. Asymptomatic urinary tract colonisation predisposes to superficial wound infection in elective orthopaedic surgery. *Int Orthop.* 2009;33 (3):847-850. doi:10.1007/s00264-008-0573-4
- 3. Bailin S, Noiseux N, Pottinger JM, et al. Screening patients undergoing total hip or knee arthroplasty with perioperative urinalysis and the effect of a practice change on antimicrobial use. *Infect Control Hosp Epidemiol.* 2017;38(3):281-286. doi:10.1017 /ice.2016.272
- 4. Nicolle LE, Gupta K, Bradley S, et al. Clinical Practice Guideline for the management of asymptomatic bacteriuria: 2018 update by the Infectious Diseases Society of America. Paper presented at: IDWeek 2018; October 7, 2018; San Diego, CA.

jamasurgery.com

JAMA Surgery Published online December 12, 2018

- **5**. de Lange MP, Sonker U, Kelder JC, de Vos R. Practice variation in treatment of suspected asymptomatic bacteriuria prior to cardiac surgery: are there differences in postoperative outcome? A retrospective cohort study. *Interact Cardiovasc Thorac Surg.* 2016;22(6):769-775. doi:10.1093/icvts/ivw039
- **6.** Soltanzadeh M, Ebadi A. Is presence of bacteria in preoperative microscopic urinalysis of the patients scheduled for cardiac surgery a reason for cancellation of elective operation? *Anesth Pain Med*. 2013;2(4):174-177. doi:10.5812/aapm.8667
- 7. Mayne AIW, Davies PSE, Simpson JM. Antibiotic treatment of asymptomatic bacteriuria prior to hip and knee arthroplasty; a systematic review of the literature. *Surgeon*. 2018;16(3):176-182. doi:10.1016 /j.surge.2017.08.007
- **8.** Maderazo EG, Judson S, Pasternak H. Late infections of total joint prostheses. A review and recommendations for prevention. *Clin Orthop Relat Res.* 1988:(229):131-142.
- 9. Pulido L, Ghanem E, Joshi A, Purtill JJ, Parvizi J. Periprosthetic joint infection: the incidence, timing, and predisposing factors. *Clin Orthop Relat Res.* 2008;466(7):1710-1715. doi:10.1007/s11999-008
- 10. Rodríguez D, Pigrau C, Euba G, et al; REIPI Group (Spanish Network for Research in Infectious Disease). Acute haematogenous prosthetic joint infection: prospective evaluation of medical and surgical management. *Clin Microbiol Infect*. 2010;16 (12):1789-1795. doi:10.1111/j.1469-0691.2010.03157.x

- 11. Kaandorp CJ, Dinant HJ, van de Laar MA, Moens HJ, Prins AP, Dijkmans BA. Incidence and sources of native and prosthetic joint infection: a community based prospective survey. *Ann Rheum Dis.* 1997;56 (8):470-475. doi:10.1136/ard.56.8.470
- 12. Sousa R, Soriano A, Guyot A. Reply to Uçkay et al. *Clin Infect Dis.* 2014;59(10):1507-1508. doi:10.1093/cid/ciu606
- 13. Cordero-Ampuero J, González-Fernández E, Martínez-Vélez D, Esteban J. Are antibiotics necessary in hip arthroplasty with asymptomatic bacteriuria? Seeding risk with/without treatment. Clin Orthop Relat Res. 2013;471(12):3822-3829. doi:10.1007/s11999-013-2868-z
- **14.** Bouvet C, Lübbeke A, Bandi C, et al. Is there any benefit in pre-operative urinary analysis before elective total joint replacement? *Bone Joint J.* 2014; 96-B(3):390-394. doi:10.1302/0301-620X.96B3 .32620
- **15.** Martínez-Vélez D, González-Fernández E, Esteban J, Cordero-Ampuero J. Prevalence of asymptomatic bacteriuria in knee arthroplasty patients and subsequent risk of prosthesis infection. *Eur J Orthop Surg Traumatol*. 2016;26(2): 209-214. doi:10.1007/s00590-015-1720-4
- **16.** Mayne AI, Davies PS, Simpson JM. Screening for asymptomatic bacteriuria before total joint arthroplasty. *BMJ*. 2016;354:i3569. doi:10.1136/bmj.i3569
- 17. Henderson WG, Daley J. Design and statistical methodology of the National Surgical Quality Improvement Program: why is it what it is? *Am J Surg.*

- 2009;198(5)(suppl):S19-S27. doi:10.1016/j.amjsurg .2009.07.025
- **18**. Branch-Elliman W, Ripollone JE, O'Brien WJ, et al. Risk of surgical site infection, acute kidney injury, and Clostridium difficile infection following antibiotic prophylaxis with vancomycin plus a beta-lactam versus either drug alone: A national propensity-score-adjusted retrospective cohort study. *PLoS Med.* 2017;14(7):e1002340. doi:10.1371 /journal.pmed.1002340
- **19.** Jung N, Lehmann C, Fätkenheuer G. The "Choosing Wisely": initiative in infectious diseases. *Infection*. 2016;44(3):283-290. doi:10.1007/s15010-015-0848-9
- **20**. Finnigan TKP, Bhutta MA, Shepard GJ. Asymptomatic bacteriuria prior to arthoplasty: how do you treat yours? [abstract]. *Orthop Proc.* 2012; 94-B(suppl XXIX):58.
- 21. Leis JA, Rebick GW, Daneman N, et al. Reducing antimicrobial therapy for asymptomatic bacteriuria among noncatheterized inpatients: a proof-of-concept study. *Clin Infect Dis.* 2014;58 (7):980-983. doi:10.1093/cid/ciu
- **22**. Drekonja DM, Gnadt C, Kuskowski MA, Johnson JR. Urine cultures among hospitalized veterans: casting too broad a net? *Infect Control Hosp Epidemiol*. 2014;35(5):574-576. doi:10.1086/675829
- **23**. Lamb MJ, Baillie L, Pajak D, et al. Elimination of Screening Urine Cultures Prior to Elective Joint Arthroplasty. *Clin Infect Dis*. 2017;64(6):806-809.